DOI: 10.1001/jamaneurol.2023.4811 ISSN: 2168-6149

Direct to Consumer Biomarker Testing for Alzheimer Disease—Are We Ready for the Insurance Consequences?

Jalayne J. Arias, Margaret Manchester, James Lah
  • Neurology (clinical)

This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.

More from our Archive